Amundi Arvinas, Inc. Transaction History

Amundi

$264 Billion
Q3 2024

A detailed history of Amundi transactions in Arvinas, Inc. stock. As of the latest transaction made, Amundi holds 7,477 shares of ARVN stock, worth $180,868. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,477

Previous 193,665 96.14%

Holding current value

$180,868

Previous $5.16 Million 96.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$23.66 - $32.73 $4.41 Million - $6.09 Million	-186,188 Reduced 96.14%	7,477 $184,000
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $7,925 - $13,089	324 Added 0.17%	193,665 $5.16 Million
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $86,548 - $124,445	-2,379 Reduced 1.22%	193,341 $7.98 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $62,762 - $187,225	4,423 Added 2.31%	195,720 $8.06 Million
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $144,903 - $208,133	7,378 Added 4.01%	191,297 $3.76 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $3.85 Million - $5.57 Million	177,192 Added 2634.04%	183,919 $4.56 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $81,614 - $116,288	3,121 Added 86.55%	6,727 $183,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $76,109 - $134,170	2,344 Added 185.74%	3,606 $123,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $45,444 - $93,690	1,262 New	1,262 $62,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $24,430 - $35,693	-371 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $27,157 - $40,019	371 New	371 $30,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.29B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.

Account